Danaher Co. (NYSE:DHR) Shares Bought by Naviter Wealth LLC

Naviter Wealth LLC lifted its holdings in shares of Danaher Co. (NYSE:DHR) by 4.9% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,663 shares of the conglomerate’s stock after purchasing an additional 358 shares during the quarter. Naviter Wealth LLC’s holdings in Danaher were worth $1,916,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. West Oak Capital LLC boosted its position in Danaher by 0.9% in the 1st quarter. West Oak Capital LLC now owns 9,776 shares of the conglomerate’s stock valued at $2,441,000 after buying an additional 85 shares during the period. Financial Security Advisor Inc. boosted its holdings in Danaher by 15.5% in the first quarter. Financial Security Advisor Inc. now owns 1,728 shares of the conglomerate’s stock valued at $432,000 after purchasing an additional 232 shares during the period. Dash Acquisitions Inc. grew its stake in Danaher by 1.6% during the 1st quarter. Dash Acquisitions Inc. now owns 62,778 shares of the conglomerate’s stock worth $15,028,000 after purchasing an additional 960 shares in the last quarter. Capital Advisors Ltd. LLC increased its holdings in Danaher by 2.4% during the 1st quarter. Capital Advisors Ltd. LLC now owns 1,888 shares of the conglomerate’s stock worth $471,000 after purchasing an additional 44 shares during the period. Finally, Woodmont Investment Counsel LLC raised its position in Danaher by 5.0% in the 1st quarter. Woodmont Investment Counsel LLC now owns 13,461 shares of the conglomerate’s stock valued at $3,361,000 after purchasing an additional 646 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR traded down $4.10 during trading hours on Tuesday, reaching $240.41. 5,062,756 shares of the company’s stock were exchanged, compared to its average volume of 2,876,110. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $269.11. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $178.07 billion, a price-to-earnings ratio of 40.75, a P/E/G ratio of 3.82 and a beta of 0.84. The company has a 50-day moving average of $256.13 and a 200 day moving average of $246.86.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business’s revenue was down 2.6% on a year-over-year basis. During the same quarter last year, the company posted $2.36 earnings per share. Research analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Buying and Selling

In other Danaher news, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Brian W. Ellis sold 4,000 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the sale, the senior vice president now directly owns 29,830 shares in the company, valued at $7,457,798.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Alan G. Spoon sold 708 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders sold a total of 148,783 shares of company stock valued at $37,536,717 over the last three months. 10.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DHR. Barclays upped their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. TD Cowen increased their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Bank of America lifted their price target on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a report on Wednesday, April 24th. Citigroup increased their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, HSBC upgraded Danaher from a “hold” rating to a “buy” rating and boosted their target price for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. Six research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $268.67.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.